CarcinoX Preventive Formulation Licensing & Collaboration Framework

17/02/2026

https://www.facebook.com/share/1883Npwthd/

Phase-1 is about to start soon.

📢 𝗠𝗔𝗛𝗔𝗠𝗔𝗡𝗔𝗡–𝗚𝗹𝗼𝗯𝗮𝗹 𝗛𝗼𝗻𝗼𝘂𝗿𝘀 𝗳𝗼𝗿 𝗛𝘂𝗺𝗮𝗻 𝗘𝘅𝗰𝗲𝗹𝗹𝗲𝗻𝗰𝗲 & 𝗖𝗼𝗻𝘀𝗰𝗶𝗼𝘂𝘀𝗻𝗲𝘀𝘀 𝗘𝘃𝗼𝗹𝘂𝘁𝗶𝗼𝗻 𝟮𝟬𝟮𝟲
Honouring Minds that Elevate Humanity

𝗠𝗔𝗛𝗔𝗠𝗔𝗡𝗔𝗡 is an international honours platform dedicated to recognising individuals who contribute to human excellence, ethical leadership, research advancement, social transformation, and the evolution of higher consciousness.

🌍 Human civilization is technologically advanced today, but is human consciousness developed in the same proportion?
This is the question that 𝗠𝗔𝗛𝗔𝗠𝗔𝗡𝗔𝗡– Global Honours for Human Excellence & Consciousness Evolution 2026 has started its journey.

Honouring Minds that Elevate Humanity

𝗠𝗔𝗛𝗔𝗠𝗔𝗡𝗔𝗡 — a registered trust (Govt. of India DARPAN & MSME Registered) — is dedicated to true human development through mental development education.
We would like to honor those who—
✔ Working in human consciousness and moral development
✔ Contributing to research and knowledge
✔ Improving society through literature and art
✔ Setting a unique example in human service
✔ Remaining dedicated to the path of human development throughout their lives

🏆 Award Categories:
• 𝗠𝗔𝗛𝗔𝗠𝗔𝗡𝗔𝗡 Human Consciousness & Integral Development Award
• 𝗠𝗔𝗛𝗔𝗠𝗔𝗡𝗔𝗡 Lifetime Achievement in Human Advancement
• 𝗠𝗔𝗛𝗔𝗠𝗔𝗡𝗔𝗡 Seva Ratna Award
• 𝗠𝗔𝗛𝗔𝗠𝗔𝗡𝗔𝗡 Research Excellence Award
• 𝗠𝗔𝗛𝗔𝗠𝗔𝗡𝗔𝗡 Award for Literature & Creative Arts
• 𝗠𝗔𝗛𝗔𝗠𝗔𝗡𝗔𝗡 Order of Human Awakening (Inclusive Distinction)

📌 Nomination & Application Opening Soon🌐 Global Participation Welcome
Let us recognise those who are shaping the future of humanity — from within.

For more details, please visit the webPag:
𝗠𝗔𝗛𝗔𝗠𝗔𝗡𝗔𝗡 – Global Honours for Human Excellence & Consciousness Evolution 2026
https://mahamanan-awards.blogspot.com/p/mahamanan-global-honours-for-human.html

WhatsApp: +91 8538805751

12/02/2026

04/02/2026

CarcinoX™ Preventive Formulation
Licensing & Collaboration Framework (Confidential)
Status: Formula is DND (Do Not Disclose). This page defines licensing terms, responsibilities, and governance for prospective licensees.

1. Overview
CarcinoX™ is a preventive formulation positioned for long-term prophylactic use. The formulation is proprietary and protected under confidentiality. Licensing is offered to qualified entities (pharma, nutraceutical, clinical research organizations) capable of executing regulated clinical development and IP protection.
Licensor: Inventor / Rights Holder (Confidential)
License Scope (Indicative):
Preventive oncology / risk-reduction domain
Human use (subject to regulatory approvals)
Territory-specific or global (as agreed)

2. Confidentiality & DND Status
The full formulation, process parameters, biomarkers, and rationale are DND.
Disclosure occurs only after ex*****on of NDA + Licensing Term Sheet.
No reverse engineering, decompilation, or analytical replication is permitted.
Breach of DND triggers immediate termination and liquidated damages.

3. Licensing Model
3.1 License Type
☐ Exclusive (Territory / Indication-bound)
☐ Co-exclusive
☐ Non-exclusive
3.2 Financial Structure (Indicative)
Upfront License Fee: Negotiable
Milestone Payments: Linked to clinical phases & approvals
Royalty: % on net sales (tiered)
Minimum Annual Commitment: Yes / No

4. Licensee Responsibilities (Mandatory)
The Licensee bears full responsibility for the following:

4.1 Clinical Development
Design, fund, and execute pre-clinical and clinical trials
Ethics committee approvals (IEC/IRB)
Compliance with ICH-GCP, local regulations
Trial registration (e.g., CTRI / ClinicalTrials.gov)

4.2 Regulatory Approvals
Dossier preparation and submissions
Engagement with national/international regulators
Post-marketing surveillance (if approved)

4.3 Patent & IP Protection
Filing, prosecution, and maintenance of patents
Territory-wise patent strategy
Defensive publications (if applicable)
All costs borne by Licensee
Note: Core IP ownership remains with Licensor unless explicitly assigned.

5. Licensor Rights & Support
Strategic scientific guidance (non-operational)
Periodic technical clarification (within NDA scope)
Right to audit development progress
Right to publish non-confidential, high-level outcomes (with consent)

6. Manufacturing & Quality (If Applicable)
GMP-compliant manufacturing mandatory
Stability, shelf-life, and quality validation by Licensee
No subcontracting without prior written approval

7. Branding & Use of Name
CarcinoX™ trademark usage subject to brand guidelines
No modification of brand or claims without approval
Preventive claims must be regulator-approved

8. Reporting & Governance
Quarterly progress reports
Annual development roadmap review
Immediate notification of adverse events or regulatory actions

9. Term, Termination & Reversion
Initial Term: X years
Termination for:
DND/NDA breach
Failure to initiate trials within agreed timeline
Regulatory non-compliance
Upon termination:
All rights revert to Licensor
Data access terms as per agreement

10. Liability & Indemnity
Licensee assumes all clinical, regulatory, and commercial risk
Indemnifies Licensor against claims, adverse outcomes, or misuse

11. Expression of Interest (EOI)
Prospective licensees must submit:
Company profile & track record
Clinical trial capability
Patent & regulatory experience
Proposed territory & indication
Shortlisted entities will be invited for NDA ex*****on.

12. Disclaimer
This page is for discussion purposes only and does not constitute a binding offer.